GlassScriptPhysician profile
Shailesh Rajguru
NPI 1336192046
$4,091.55
in general payments reported to CMS, 2019-2025
48 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $270 · 2021: $569 · 2022: $71.18 · 2023: $579 · 2024: $788 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $342.15 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $317.13 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $309.79 | 2019-2022 | |
| Lilly USA, LLC | $228.46 | 2019-2025 | Amyvid, Kisunla |
| Sunovion Pharmaceuticals INC. | $226.73 | 2019-2021 | |
| Ucb, INC. | $207.33 | 2019-2021 | |
| Emd Serono, INC. | $206.86 | 2024-2025 | Mavenclad |
| Amgen INC. | $176.84 | 2019-2021 | |
| Argenx US, INC. | $161.57 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $155.72 | 2019-2021 | |
| Lundbeck LLC | $135.82 | 2020-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $127.28 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $114.32 | 2019-2024 | Ultomiris |
| Genentech USA, INC. | $113.94 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Mdd US Operations, LLC | $94.77 | 2020-2025 | Gocovri, Gocovri |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Rajguru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.